中药联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化疗效系统评价*

doi:10.3969/j.issn.1672-5069.2015.04.012

Abstract

Abstract: Objectives To evaluate the effectiveness and safety of Chinese herbal medicine combined with ursodeoxycholic acid （UDCA） in treatment of patients with primary biliary cirrhosis （PBC）. Methods The randomized controlled trials（RCT） articles on combination of herbal medicine and UDCA in treatment of patients with PBC were retrieved from China national knowledge infrastructure （CNKI），Wanfang academic journal database，Vip journal database（VIP），Medline and Pubmed from November 2009 to November 2014 by Cochrane systemic review method and materials were analyzed by Revman5.3 software. Results We obtained 10 randomized controlled trials and their Jadad scores were one to three. Eight out of the ten RCT giving efficacy included 368 patients with PBC，with 187 with combination treatment and 181 with UDCA alone. Meta analysis showed that the effectiveness rate in combination group was statistically significant different as compared to that in UDCA alone [OR=3.83，95%CI （2.09，7.02），P<0.0001]；the serum ALP，GGT，TBIL，ALT，AST，TBA levels in combination group decreased more obviously than in control. Conclusion Chinese herbal medicine combined with UDCA in treatment of patients with PBC is promising，but the studies needs more evidences to prove it.

Key words: Primary biliary cirrhosis, Chinese herbal medicine, Ursodeoxycholic acid, Meta-analysis

Kong Xianglu，Guo Xiaoxia. Systemic review of Chinese herbal medicine combined with ursodeoxycholic acid in treatment of patients with primary biliary cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 379-382.

References

[1] 姚光弼. 临床肝脏病学. 2版.上海:上海科学技术出版社，2011:332-333.
[2] Kei D，Lindor M，Eric G，et al. Primary biliary cirrhosis. The American Association for the study Liver Diseases practice guidelines. J Hepatol，2009，50（1）:291-308.
[3] Hirschfield GM. Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol，2011，25（6）:701-712.
[4] Baldursdottir TR，Bergmann OM，Jonasson JG，et al. The epidemiology and natural history of primary biliary cirrhosis:a nationwide population-based study. Eur J Gastroenterol Hepatol，2012，24（7）:824-830.
[5] Wahl I，Feige A，Lowe B，et al. Primary biliary“cirrhosis”:Time to replace a misnomer.Hepatology，2014，Jun 13. doi:10.1002/hep.27263[Epub ahead of print].
[6] 汤雯，贾继东. 2012年自身免疫性肝脏疾病基础和临床进展. 肝脏，2013，18（8）:559-562.
[7] 宋春荣，南然.原发性胆汁性肝硬化中西医研究概况. 河南中医，2013，33（7）:1073-1075.
[8] 窦宇明，沈桂堂，耿爱文，等. 柴胡疏肝汤联合熊去氧胆酸治疗原发性胆汁性肝硬化32例. 中西医结合肝病杂志，2010，20（4）:242-244.
[9] 苏春芝，钟锐. 化浊解毒调肝方对原发性胆汁性肝硬化患者淤胆指标的影响. 中医临床研究，2011，3（5）:58-60.
[10] 韩会敏.归芍活血汤联合熊去氧胆酸治疗原发性胆汁性肝硬化疗效观察. 南京:南京中医药大学出版社，2012：120-128.
[11] 陈宇锋.疏肝利胆活血化瘀方联合熊去氧胆酸对原发性胆汁性肝硬化的临床疗效观察.南京:南京中医药大学出版社，2013：142-148.
[12] 南然.清木丹颗粒联合熊去氧胆酸胶囊对原发性胆汁性肝硬化的疗效评价. 陕西:陕西中医学院出版社，2013：88-92.
[13] 廖娇.正化瘀法联合熊去氧胆酸治疗原发性胆汁性肝硬化的临床研究. 湖北:湖北中医药大学出版社，2014：154-159.
[14] 李猛，李振前，邓治正. 活血化瘀法联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化30例. 江西中医药，2010，41（332）:39-41.
[15] 袁庆亮. 疏肝解毒化痰通络方联合熊去氧胆酸治疗原发性胆汁性肝硬化的临床研究. 湖北:湖北中医药大学出版社，2014：132-136.
[16] 叶小丹，朱肖鸿. 中西医结合治疗肝郁脾虚型原发性胆汁性肝硬化患者的疗效观察. 中医药学报，2013，41（4）:116-117.
[17] 周啟亮.滋肾活血祛风方联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化29例临床观察. 湖北:湖北中医药大学出版社，2011：86-90.
[18] Silveira MG，Burnt EM，Heathcote J，et al. American association for the study of liver diseases endpoints conference:design and endpoints for clinical trials in primary biliary cirrhosis. J Hepatol，2010，25（1）:349-359.
[19] Nguyen DL，Juran BD，Lazaridis KN. Primary biliary cirrhosis. Best Pract Res Clin Gastroenterol，2010，24（5）:647-654.
[20] 张宁，宫嫚，周双男，等. 原发性胆汁性肝硬化中医证候分型文献分析. 实用肝脏病杂志，2013，16（5）:445-447.
[21] 李红玉，薛博瑜. 原发性胆汁性肝硬化中医证治用药规律的文献研究. 中国实验方剂学杂志，2014，20（3）:209-213.

Systemic review of Chinese herbal medicine combined with ursodeoxycholic acid in treatment of patients with primary biliary cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[2]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[3]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[4]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.
[5]	Lu Lungen. Cholestatic liver diseases：What we know and how to deal with [J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.
[6]	Zhang Xuan, Tang Xiaoyun, Tang Chunyin, et al. Effect of Chinese herbal medicine on intestinal microflora in mice with D-galactosamine/LPS-induced acute liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 478-481.
[7]	Liu Yingchuan, Zhao Pengcheng, You Ting, et al.. Changes of peripheral blood 25-（OH） 2-D3 levels and peripheral T lymphocyte subsets in patients with primary biliary cirrhosis receiving vitamin D supplementation and ursodeoxycholic acid treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 907-910.
[8]	Liu Jinguo, Wang Baokui. Efficacy of Fufangbiejia Ruanganpian and ursodeoxycholic acid combination in the treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 340-343.
[9]	Li Min, Li Hong, Fu Zhiyue. Efficacy of adenosylmethionine combined with ursodeoxycholic acid in treatment of infants with cytomegalovirus infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 461-462.
[10]	Zhang Haiyue, Wang Luwen, Liu Feifei, et al. Serum HBsAg levels in prognosis of serological response to nucleos（t）ide analog therapy in patients with HBeAg positive chronic hepatitis B:a Meta-analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 191-195.
[11]	Jiao Fangzhou, Zhang Haiyue, Zhang Wenbin, et al. Efficacy of combination sofosbuvir and pegylated interferon-α in treatment of patients with chronic hepatitis C:a Meta-analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 220-224.
[12]	Qin Wei, Chen Yuping, Yang Zhao, et al. Expression of transforming growth factor β-1 in liver tissues of patients with primary biliary cirrhosis and its relationship with liver fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 237-240.
[13]	Chen Xiaojun, Song Yang. Changes of peripheral blood T lymphocyte subsets and efficacy of ursodesoxycholic acid and vitamin D combination in treatment of patients with primary biliary cholangitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 80-83.
[14]	Tao Mingling, Zhang Shibin, Wu Yanjing, et al.. Non-invasive predictors of esophageal varices in patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 439-442.
[15]	Liu Funa, Liu Jiangkui, Shen Yihui.. Efficacy of ursodeoxycholic acid and prednisolone combination in treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 443-446.